Company & Sponsor Intelligence
Forest Laboratories
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed5
Countries1
Therapeutic footprint
alzheimersautismdepression
Indexed studies
NCT00107120The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT01592786An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT00872898Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT00090116The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00644358A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT01592773Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
autism · United StatesPHASE2
autism · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →